Drugs / CYC116
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00560716 | Jun 2007 → Jan 2009 | cancer | Cyclacel Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYC116 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00560716 ↗ |
| Action | Inhibit | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL482967 ↗1“Aurora kinase inhibitor” NCT00560716 ↗ |
| Modality | Small molecule | — CHEMBL482967 ↗ |
| Route | Oral | “Oral Aurora Kinase Inhibitor” NCT00560716 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL482967 ↗ |